X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (214) 214
Publication (30) 30
Patent (14) 14
Conference Proceeding (5) 5
Book Chapter (2) 2
Web Resource (2) 2
Book / eBook (1) 1
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (92) 92
index medicus (64) 64
female (58) 58
hematology (56) 56
male (52) 52
middle aged (52) 52
adult (49) 49
oncology (47) 47
aged (41) 41
prognosis (40) 40
chemotherapy (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
positron-emission-tomography (26) 26
adolescent (24) 24
lymphoma (23) 23
diagnosis (22) 22
lymphomas (21) 21
positron-emission tomography (21) 21
treatment outcome (21) 21
disease (20) 20
fluorodeoxyglucose f18 (19) 19
disease-free survival (18) 18
fdg-pet (18) 18
positron-emission tomography - methods (18) 18
cancer (17) 17
hodgkin disease - diagnostic imaging (17) 17
hodgkin disease - drug therapy (17) 17
neoplasm staging (17) 17
hodgkin's disease (16) 16
therapy (16) 16
b-cell lymphoma (15) 15
radiology, nuclear medicine & medical imaging (15) 15
retrospective studies (15) 15
calculating (14) 14
computing (14) 14
counting (14) 14
hodgkin disease - pathology (14) 14
hodgkin lymphoma (14) 14
physics (14) 14
survival analysis (14) 14
tomography (14) 14
image data processing or generation, in general (13) 13
non-hodgkins-lymphoma (13) 13
nuclear medicine (13) 13
pet (13) 13
surgery (13) 13
survival (13) 13
aged, 80 and over (12) 12
human necessities (12) 12
hygiene (12) 12
identification (12) 12
medical or veterinary science (12) 12
response assessment (12) 12
tomography, x-ray computed (12) 12
medicine & public health (11) 11
pet imaging (11) 11
stem-cell transplantation (11) 11
young adult (11) 11
abridged index medicus (10) 10
doxorubicin (10) 10
follow-up studies (10) 10
hodgkin disease - diagnosis (10) 10
rituximab (10) 10
combined modality therapy (9) 9
cyclophosphamide - administration & dosage (9) 9
hodgkin disease - therapy (9) 9
lymphoma - diagnostic imaging (9) 9
positron emission tomography (9) 9
prognostic score (9) 9
prognostic value (9) 9
transplantation, autologous (9) 9
antineoplastic agents - therapeutic use (8) 8
care and treatment (8) 8
clinical trials (8) 8
criteria (8) 8
doxorubicin - administration & dosage (8) 8
international workshop (8) 8
italy (8) 8
multivariate analysis (8) 8
radiotherapy (8) 8
reproducibility of results (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
computed tomography (7) 7
hematology, oncology and palliative medicine (7) 7
hematopoietic stem cell transplantation (7) 7
imaging / radiology (7) 7
predictive value of tests (7) 7
progression-free survival (7) 7
prospective studies (7) 7
radiopharmaceuticals (7) 7
risk (7) 7
term-follow-up (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (6) 6
bleomycin (6) 6
bone-marrow-transplantation (6) 6
cardiology (6) 6
dacarbazine (6) 6
f-18-fdg pet (6) 6
follicular lymphoma (6) 6
hemic and lymphatic diseases (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 08/2019, Volume 60, Issue 8, pp. 1094 - 1095
Journal Article
2016, ISBN 9783319317977
This book describes the various contributions of positron emission tomography (PET) to the management of Hodgkin lymphoma and considers key issues in its use.... 
Medicine | Nuclear medicine | Hematology | Radiology | Oncology | Radiotherapy
Web Resource
2016, ISBN 9783319317977
This book describes the various contributions of positron emission tomography (PET) to the management of Hodgkin lymphoma and considers key issues in its use.... 
Medicine | Nuclear medicine | Hematology | Radiology | Oncology | Radiotherapy
Web Resource
2016, 1st ed. 2016, ISBN 3319317954, 143
This book describes the various contributions of positron emission tomography (PET) to the management of Hodgkin lymphoma and considers key issues in its use.... 
Clinical & internal medicine | Radiotherapy | Oncology | Nuclear Medicine | Medicine & Public Health | Hematology | Diagnostic Radiology | Tomography, Emission | Hodgkin's disease
eBook
Blood, ISSN 0006-4971, 11/2017, Volume 130, Issue 20, pp. 2154 - 2155
A number of disease-or host-related markers have been proposed to predict treatment outcome in relapsed/refractory Hodgkin lymphoma (HL). In this issue of... 
HODGKINS LYMPHOMA | SURVIVAL | INTERIM | VOLUME | PROGNOSTIC SCORE | HEMATOLOGY | CHEMOTHERAPY | Fluorodeoxyglucose F18 | Positron-Emission Tomography | Hodgkin Disease | Humans | Neoplasm Recurrence, Local
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, 3/2016, Volume 43, Issue 3, pp. 414 - 421
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 7, pp. 814 - 824
Purpose High-dose chemotherapy with peripheral blood progenitor cell (PBPC) autograft is effective in high-risk lymphoma, particularly with the addition of... 
PROGENITOR CELLS | THERAPY | ONCOLOGY | COMPETING RISK | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | AUTOLOGOUS TRANSPLANTATION | NON-HODGKINS-LYMPHOMA | FOLLICULAR LYMPHOMA | STEM-CELL TRANSPLANTATION | MYELODYSPLASTIC SYNDROME | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Hodgkin Disease - pathology | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Lymphoma - mortality | Dose-Response Relationship, Drug | Young Adult | Lymphoma - therapy | Time Factors | Statistics, Nonparametric | Hodgkin Disease - mortality | Adult | Female | Lymphoma - pathology | Retrospective Studies | Lymphoma, B-Cell - mortality | Risk Assessment | Immunologic Factors - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Rituximab | Treatment Outcome | Combined Modality Therapy | Transplantation, Autologous - methods | Neoplasms, Second Primary - epidemiology | Disease-Free Survival | Stem Cell Transplantation - methods | Lymphoma, T-Cell - therapy | Hodgkin Disease - therapy | Adolescent | Lymphoma, B-Cell - pathology | Lymphoma, T-Cell - pathology | Survival Analysis | Transplantation, Autologous - adverse effects | Aged | Lymphoma, T-Cell - mortality | Cohort Studies | Stem Cell Transplantation - adverse effects
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 4, pp. 331 - 344
BACKGROUND Brentuximab vedotin is an anti-CD30 antibody-drug conjugate that has been approved for relapsed and refractory Hodgkin's lymphoma. METHODS We... 
TRIAL | ABVD | MEDICINE, GENERAL & INTERNAL | POSITRON-EMISSION-TOMOGRAPHY | RESPONSE CRITERIA | DISEASE | PROGNOSTIC SCORE | OPEN-LABEL | TOXICITY | INTERGROUP | COOPERATIVE-ONCOLOGY-GROUP | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Immunoconjugates - administration & dosage | Young Adult | Aged, 80 and over | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Immunoconjugates - adverse effects | Dacarbazine - administration & dosage | Immunologic Factors - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Immunologic Factors - adverse effects | Neoplasm Staging | Vinblastine | Hematology | Toxicity | Prophylaxis | Clinical trials | Oncology | Peripheral neuropathy | Cancer therapies | Doxorubicin | Survival | Lymphoma | Medicine | Dacarbazine | Chemotherapy | Bleomycin | CD30 antigen | Granulocyte colony-stimulating factor | Death | Colony-stimulating factor | Lymphomas | Leukocytes (granulocytic) | Drug dosages | Hodgkin's disease | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Nuclear Medicine, ISSN 0161-5505, 07/2013, Volume 54, Issue 7, p. 1082
  Hodgkin lymphoma (HL) is a curable disease with currently available chemotherapy regimens. Major late morbidities can potentially be avoided in most... 
Chemotherapy | Risk assessment | Clinical trials | Lymphomas | Radiation therapy | Tumors
Journal Article
Haematologica, ISSN 0390-6078, 7/2010, Volume 95, Issue 7, pp. 1046 - 1048
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 07/2013, Volume 54, Issue 7, pp. 1082 - 1093
Journal Article
Seminars in Nuclear Medicine, ISSN 0001-2998, 01/2018, Volume 48, Issue 1, pp. 17 - 27
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition... 
B-CELL LYMPHOMA | EARLY F-18-FDG PET | POSITRON-EMISSION-TOMOGRAPHY | DEAUVILLE 5-POINT SCALE | COMBINED-MODALITY THERAPY | PROGRESSION-FREE SURVIVAL | RESPONSE ASSESSMENT | STAGE HODGKINS LYMPHOMA | PROGNOSTIC VALUE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PERIPHERAL T-CELL | Pets | Chemotherapy | Non-Hodgkin's lymphomas | PET imaging | T cells | Cancer
Journal Article